Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Fargo, ND
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Beachwood, OH
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Beachwood, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Middleburg Heights, OH
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Ashland, OR
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Ashland, OR
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Knoxville, TN
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Memphis, TN
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Austin, TX
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Houston, TX
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Mission, TX
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Mission, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Norfolk, VA
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated:  4/7/2016
mi
from
Olivos,
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
Status: Enrolling
Updated: 4/7/2016
mi
from
Olivos,
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site #10
mi
from
Goodyear, AZ
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site #10
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #42
mi
from
Greenbrae, CA
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #42
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #39
mi
from
Denver, CO
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #39
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #34
mi
from
Detroit, MI
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #34
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #34
mi
from
St. Louis, MO
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #34
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #36
mi
from
Las Vegas, NV
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #36
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: # 37
mi
from
Oklahoma City, OK
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: # 37
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: # 33
mi
from
San Antonio, TX
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: # 33
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #74
mi
from
Arkhangelsk,
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #74
mi
from
Arkhangelsk,
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Central Georgia Gynecologic Oncology
mi
from
Macon, GA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Central Georgia Gynecologic Oncology
mi
from
Macon, GA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Methodist West Hospital
mi
from
West Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Methodist West Hospital
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Borgess Medical Center
mi
from
Kalamazoo, MI
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials